Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). $55M funded under five-year facility; up to $150M total capacity supports refinancing and corporate liquidity.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $55M funded under five-year facility; up to $150M total capacity supports refinancing and corporate liquidity
- Tranche B $20M contingent on FDA approval for Anaphylm before June 30, 2027
- Tranche C $25M requires Tranche B borrowing and specified net-sales milestone by December 31, 2027
- Interest at three-month SOFR plus 6.25%, with 2.75% floor and quarterly interest-only payments
- Significant lender protections: cash minimums, Anaphylm sales covenants, collateral liens, prepayment premiums, and potential paydown if approval misses December 31, 2027
Item 1.02 · Termination of a Material Definitive Agreement
- $45.0 million outstanding notes repaid in full under the terminated Indenture
- Existing lender commitments and security interests in company assets discharged
- Refinancing incurred a prepayment fee and final payment fee without penalties
- Credit Agreement proceeds facilitate replacement of the prior secured debt arrangement
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Financial results and business-update details available in Exhibit 99.1
- Press release issued May 13, 2026
Item 3.02 · Unregistered Sales of Equity Securities
- Five-year warrants issued alongside Credit Agreement financing, creating potential future common-stock dilution
- Tranche A warrant coverage equals 1.75% of principal divided by the prior 30-day VWAP
- Tranche B and C warrant terms use the lower of Tranche A VWAP or subsequent 30-day VWAP
- Exercise prices tied to applicable VWAPs, potentially lowering strike prices for later drawdowns
- Warrant shares to be registered; issuance relies on Securities Act Section 4(a)(2) private-placement exemption
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for meetings with institutional investors and analysts
- Presentation attached as Exhibit 99.3, containing the substantive investor-facing information
- Company may amend or update the disclosed materials through subsequent filings or other communications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.